Annual CFF
$20.12 M
-$39.27 M-66.13%
31 December 2023
Summary:
ProShares UltraPro Short Nasdaq Biotechnology annual cash flow from financing activities is currently $20.12 million, with the most recent change of -$39.27 million (-66.13%) on 31 December 2023. ZBIO annual CFF is now -66.13% below its all-time high of $59.39 million, reached on 31 December 2022.ZBIO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$233.98 M
+$56.24 M+31.64%
30 September 2024
Summary:
ProShares UltraPro Short Nasdaq Biotechnology quarterly cash flow from financing activities is currently $233.98 million, with the most recent change of +$56.24 million (+31.64%) on 30 September 2024. Over the past year, it has increased by +$213.98 million (+1069.90%). ZBIO quarterly CFF is now at all-time high.ZBIO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$411.15 M
+$213.98 M+108.52%
30 September 2024
Summary:
ProShares UltraPro Short Nasdaq Biotechnology TTM cash flow from financing activities is currently $411.15 million, with the most recent change of +$213.98 million (+108.52%) on 30 September 2024. Over the past year, it has increased by +$391.15 million (+1955.78%). ZBIO TTM CFF is now at all-time high.ZBIO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ZBIO Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -66.1% | +1069.9% | +1955.8% |
| 3 y3 years | - | - | - |
| 5 y5 years | - | - | - |
ZBIO Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -66.1% | at low | at high | >+9999.0% | at high | +2015.4% |
| 5 y | 5 years | -66.1% | at low | at high | >+9999.0% | at high | +2015.4% |
| alltime | all time | -66.1% | at low | at high | >+9999.0% | at high | +2015.4% |
ProShares UltraPro Short Nasdaq Biotechnology Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $233.98 M(+31.6%) | $411.15 M(+108.5%) |
| June 2024 | - | $177.74 M(<-9900.0%) | $197.18 M(+914.5%) |
| Mar 2024 | - | -$614.00 K(-1328.0%) | $19.44 M(-3.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $20.12 M(-66.1%) | $50.00 K(-99.8%) | $20.05 M(+0.3%) |
| Sept 2023 | - | $20.00 M | $20.00 M |
| Dec 2022 | $59.39 M | - | - |
FAQ
- What is ProShares UltraPro Short Nasdaq Biotechnology annual cash flow from financing activities?
- What is the all time high annual CFF for ProShares UltraPro Short Nasdaq Biotechnology?
- What is ProShares UltraPro Short Nasdaq Biotechnology annual CFF year-on-year change?
- What is ProShares UltraPro Short Nasdaq Biotechnology quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for ProShares UltraPro Short Nasdaq Biotechnology?
- What is ProShares UltraPro Short Nasdaq Biotechnology quarterly CFF year-on-year change?
- What is ProShares UltraPro Short Nasdaq Biotechnology TTM cash flow from financing activities?
- What is the all time high TTM CFF for ProShares UltraPro Short Nasdaq Biotechnology?
- What is ProShares UltraPro Short Nasdaq Biotechnology TTM CFF year-on-year change?
What is ProShares UltraPro Short Nasdaq Biotechnology annual cash flow from financing activities?
The current annual CFF of ZBIO is $20.12 M
What is the all time high annual CFF for ProShares UltraPro Short Nasdaq Biotechnology?
ProShares UltraPro Short Nasdaq Biotechnology all-time high annual cash flow from financing activities is $59.39 M
What is ProShares UltraPro Short Nasdaq Biotechnology annual CFF year-on-year change?
Over the past year, ZBIO annual cash flow from financing activities has changed by -$39.27 M (-66.13%)
What is ProShares UltraPro Short Nasdaq Biotechnology quarterly cash flow from financing activities?
The current quarterly CFF of ZBIO is $233.98 M
What is the all time high quarterly CFF for ProShares UltraPro Short Nasdaq Biotechnology?
ProShares UltraPro Short Nasdaq Biotechnology all-time high quarterly cash flow from financing activities is $233.98 M
What is ProShares UltraPro Short Nasdaq Biotechnology quarterly CFF year-on-year change?
Over the past year, ZBIO quarterly cash flow from financing activities has changed by +$213.98 M (+1069.90%)
What is ProShares UltraPro Short Nasdaq Biotechnology TTM cash flow from financing activities?
The current TTM CFF of ZBIO is $411.15 M
What is the all time high TTM CFF for ProShares UltraPro Short Nasdaq Biotechnology?
ProShares UltraPro Short Nasdaq Biotechnology all-time high TTM cash flow from financing activities is $411.15 M
What is ProShares UltraPro Short Nasdaq Biotechnology TTM CFF year-on-year change?
Over the past year, ZBIO TTM cash flow from financing activities has changed by +$391.15 M (+1955.78%)